264 related articles for article (PubMed ID: 15899610)
21. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.
Lidgren M; Wilking N; Jönsson B; Rehnberg C
Acta Oncol; 2008; 47(6):1018-28. PubMed ID: 18607881
[TBL] [Abstract][Full Text] [Related]
23. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
[TBL] [Abstract][Full Text] [Related]
24. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
Hicks DG; Tubbs RR
Hum Pathol; 2005 Mar; 36(3):250-61. PubMed ID: 15791569
[TBL] [Abstract][Full Text] [Related]
26. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.
Grimm EE; Schmidt RA; Swanson PE; Dintzis SM; Allison KH
Am J Clin Pathol; 2010 Aug; 134(2):284-92. PubMed ID: 20660333
[TBL] [Abstract][Full Text] [Related]
27. HER2 status in breast cancer--an example of pharmacogenetic testing.
Kroese M; Zimmern RL; Pinder SE
J R Soc Med; 2007 Jul; 100(7):326-9. PubMed ID: 17606754
[TBL] [Abstract][Full Text] [Related]
28. HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment.
Barron JJ; Cziraky MJ; Weisman T; Hicks DG
Oncologist; 2009 Aug; 14(8):760-8. PubMed ID: 19684074
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
[TBL] [Abstract][Full Text] [Related]
30. Should HER2 status be routinely measured for all breast cancer patients?
Ravdin PM
Semin Oncol; 1999 Aug; 26(4 Suppl 12):117-23. PubMed ID: 10482203
[TBL] [Abstract][Full Text] [Related]
31. Tissue microarray technology in breast cancer HER2 diagnostics.
Egervari K; Szollosi Z; Nemes Z
Pathol Res Pract; 2007; 203(3):169-77. PubMed ID: 17292562
[TBL] [Abstract][Full Text] [Related]
32. Impact of clinical and non-clinical factors on the choice of HER2 test for breast cancer.
Ashok M; Griffin P; Halpern M
Cancer Invest; 2010 Aug; 28(7):735-42. PubMed ID: 20590449
[TBL] [Abstract][Full Text] [Related]
33. [Her2/neu receptor: one of the basic factors rendering tailored therapy feasible in breast cancer patients].
Kulka J
Orv Hetil; 2005 Apr; 146(17):785-90. PubMed ID: 17918634
[TBL] [Abstract][Full Text] [Related]
34. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
[TBL] [Abstract][Full Text] [Related]
35. The use of HER2 testing in the management of breast cancer.
Ravdin P
Semin Oncol; 2000 Oct; 27(5 Suppl 9):33-42. PubMed ID: 11049055
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
Mass RD; Press MF; Anderson S; Cobleigh MA; Vogel CL; Dybdal N; Leiberman G; Slamon DJ
Clin Breast Cancer; 2005 Aug; 6(3):240-6. PubMed ID: 16137435
[TBL] [Abstract][Full Text] [Related]
37. What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.
Umemura S; Osamura RY; Akiyama F; Honma K; Kurosumi M; Sasano H; Toyoshima S; Tsuda H; Rüschoff J; Sakamoto G
Am J Clin Pathol; 2008 Dec; 130(6):883-91. PubMed ID: 19019764
[TBL] [Abstract][Full Text] [Related]
38. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
Marcom PK; Isaacs C; Harris L; Wong ZW; Kommarreddy A; Novielli N; Mann G; Tao Y; Ellis MJ
Breast Cancer Res Treat; 2007 Mar; 102(1):43-9. PubMed ID: 16897431
[TBL] [Abstract][Full Text] [Related]
39. [Breast cancer and herceptin].
Cornez N; Piccart MJ
Bull Cancer; 2000 Nov; 87(11):847-58. PubMed ID: 11125293
[TBL] [Abstract][Full Text] [Related]
40. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
